Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Bibliographic Details
Main Authors:	Fabio Guolo, Claudio Cerchione, Chiara Vernarecci, Alessandro Isidori
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Oncology
Subjects:	acute myeloid leukemia (AML) minimal residual disease (MRD) immunotherapy allogeneic stem cell transplantation leukemic stem cell (LSC)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1020185/full

Similar Items

MRD Tailored Therapy in AML: What We Have Learned So Far
by: Lok Lam Ngai, et al.
Published: (2021-01-01)

CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells
by: Lucas Touzet, et al.
Published: (2019-03-01)

Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect
by: H. Moses Murdock, et al.
Published: (2024-03-01)

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
by: Justin Loke, et al.
Published: (2021-05-01)

Understanding the Hedgehog Signaling Pathway in Acute Myeloid Leukemia Stem Cells: A Necessary Step toward a Cure
by: Daniel Lainez-González, et al.
Published: (2021-03-01)

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia
by: Laurène Pousse, et al.
Published: (2023-05-01)

Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells
by: Lindsey A. Murphy, et al.
Published: (2023-12-01)

Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia
by: Azza M. Kamel, et al.
Published: (2022-04-01)

LSD1 inhibition modulates transcription factor networks in myeloid malignancies
by: Emily E. Hartung, et al.
Published: (2023-03-01)

Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China
by: Jie Ding, et al.
Published: (2024-12-01)

The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia
by: Andrew Wu, et al.
Published: (2023-03-01)

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
by: Nikhil Patkar, et al.
Published: (2019-06-01)

Treatment options for acute myeloid leukemia patients aged <60 years
by: Giuseppe Visani, et al.
Published: (2022-10-01)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)

Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
by: Toshiki Terao, et al.
Published: (2019-04-01)

Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
by: Patrizia Chiusolo, et al.
Published: (2022-08-01)

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission
by: Xi Jia, et al.
Published: (2024-02-01)

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia
by: Justin Loke, et al.
Published: (2021-04-01)

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia
by: Joan So, et al.
Published: (2022-05-01)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
by: Mark P. Chao, et al.
Published: (2020-01-01)

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
by: Monica Bocchia, et al.
Published: (2018-05-01)

GABP is necessary for stem/progenitor cell maintenance and myeloid differentiation in human hematopoiesis and chronic myeloid leukemia
by: Georgi Manukjan, et al.
Published: (2016-05-01)

Liquid biopsies and minimal residual disease in myeloid malignancies
by: Sabine Allam, et al.
Published: (2023-05-01)

Rare myeloid sarcoma/acute myeloid leukemia with adrenal mass after allogeneic mobilization peripheral blood stem cell transplantation
by: Ya-Fei Wang, et al.
Published: (2013-12-01)

Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects
by: Elena N. Parovichnikova, et al.
Published: (2021-07-01)

Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells
by: Josephine Wesely, et al.
Published: (2020-06-01)

Successful Outcome of a Case of Acute Myeloid Leukemia with t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis
by: Guangqiang Meng, et al.
Published: (2019-11-01)

Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia
by: Heejoo Han, et al.
Published: (2021-03-01)

Reactive Oxygen Species and Metabolism in Leukemia: A Dangerous Liaison
by: Marta Romo-González, et al.
Published: (2022-06-01)

Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
by: Kunadt D, et al.
Published: (2021-09-01)

Dendritic cell-based immunotherapy for myeloid leukemias
by: Christian Martijn Schürch, et al.
Published: (2013-12-01)

Pilot Study on Mass Spectrometry–Based Analysis of the Proteome of CD34+CD123+ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia
by: Johannes R. Schmidt, et al.
Published: (2018-02-01)

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
by: Henrike Jacobi, et al.
Published: (2023-07-01)

MRD in AML: The Role of New Techniques
by: Maria Teresa Voso, et al.
Published: (2019-07-01)

Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing
by: Jianbiao Zhou, et al.
Published: (2024-04-01)

Mitochondrial abnormalities as a target of intervention in acute myeloid leukemia
by: Elissa Tjahjono, et al.
Published: (2025-01-01)

The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia
by: Vilma Dembitz, et al.
Published: (2021-05-01)

Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias
by: Xingjian Zhai, et al.
Published: (2022-07-01)

Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2
by: Rachel Culp-Hill, et al.
Published: (2023-03-01)

Put in a “Ca<sup>2+</sup>ll” to Acute Myeloid Leukemia
by: Clara Lewuillon, et al.
Published: (2022-02-01)